<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Elam RE</submitter><funding>NIA NIH HHS</funding><pagination>20</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12783237</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>21(1)</volume><pubmed_abstract>In the U.S's largest integrated health system, during a 24-year period (1999-2022), bisphosphonate treatment initiation for fracture prevention in men shifted towards higher-risk populations, including older men and those with prior fracture and frailty.&lt;h4>Purpose&lt;/h4>To evaluate 24-year trends in bisphosphonate (BP) initiation among older U.S. male Veterans and shifts in demographic and clinical characteristics of BP-treated men over time.&lt;h4>Methods&lt;/h4>U.S. national Veterans Health Administration (VHA) data (1999-2022) were queried to identify men aged ≥ 50 years with a first prescription for an FDA-approved BP for fracture prevention. Age, race, ethnicity, BP drug and route, prior fracture, and, in those aged ≥ 65 years, Veterans Affairs Frailty Index (VA-FI), were examined across fiv</pubmed_abstract><journal>Archives of osteoporosis</journal><pubmed_title>Shifting bisphosphonate prescribing patterns for fracture prevention: a 24-year national surveillance of men in the U.S. Veterans Health Administration.</pubmed_title><pmcid>PMC12783237</pmcid><funding_grant_id>R01 AG079118</funding_grant_id><funding_grant_id>R01AG079118</funding_grant_id><pubmed_authors>Schousboe JT</pubmed_authors><pubmed_authors>Huo Z</pubmed_authors><pubmed_authors>Elam RE</pubmed_authors><pubmed_authors>Adler RA</pubmed_authors><pubmed_authors>Weaver FM</pubmed_authors><pubmed_authors>Barzilay J</pubmed_authors><pubmed_authors>Budde E</pubmed_authors><pubmed_authors>Carbone LD</pubmed_authors><pubmed_authors>Lo JC</pubmed_authors><pubmed_authors>Fink HA</pubmed_authors><pubmed_authors>Jacob R</pubmed_authors><pubmed_authors>Ott SM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Shifting bisphosphonate prescribing patterns for fracture prevention: a 24-year national surveillance of men in the U.S. Veterans Health Administration.</name><description>In the U.S's largest integrated health system, during a 24-year period (1999-2022), bisphosphonate treatment initiation for fracture prevention in men shifted towards higher-risk populations, including older men and those with prior fracture and frailty.&lt;h4>Purpose&lt;/h4>To evaluate 24-year trends in bisphosphonate (BP) initiation among older U.S. male Veterans and shifts in demographic and clinical characteristics of BP-treated men over time.&lt;h4>Methods&lt;/h4>U.S. national Veterans Health Administration (VHA) data (1999-2022) were queried to identify men aged ≥ 50 years with a first prescription for an FDA-approved BP for fracture prevention. Age, race, ethnicity, BP drug and route, prior fracture, and, in those aged ≥ 65 years, Veterans Affairs Frailty Index (VA-FI), were examined across fiv</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-06-06T11:44:40.49Z</modification><creation>2026-05-30T03:07:19.412Z</creation></dates><accession>S-EPMC12783237</accession><cross_references><pubmed>41504976</pubmed><doi>10.1007/s11657-025-01635-z</doi></cross_references></HashMap>